Neuroblastoma
483
74
107
237
Key Insights
Highlights
Success Rate
82% trial completion
Published Results
71 trials with published results (15%)
Research Maturity
237 completed trials (49% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
10.6%
51 terminated out of 483 trials
82.3%
-4.2% vs benchmark
6%
31 trials in Phase 3/4
30%
71 of 237 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 237 completed trials
Clinical Trials (483)
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Neuroblastoma Maintenance Therapy Trial
Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
Haploidentical Donor Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Neuroblastoma
Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
68Ga-DOTATATE Neuroblastoma Imaging Pilot
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01